← All claims

Metabolic & Cardiometabolic

glucose variability predicts cardiovascular risk in non-diabetics

In plain terms: Does blood-sugar "variability" on a CGM predict heart disease in healthy people?

Contested Metabolic & Cardiometabolic 🔬 Includes disconfirming
RefutedContestedStrong support
consensus score 0.17

Variability tracks surrogate risk markers, but direct hard-outcome CV evidence in non-diabetics is limited, so the "predicts CVD" claim is not established.

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: Population patterns (Observational)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

3 support 0 contradict 1 tested null 8 mixed · 12 sources, 3 independent groups

The evidence (12)

SourceGradeStanceQualityFinding
Sato
2026 · J Clin Endocrinol Metab
observational mixed moderate Lower CGM-derived time-in-range was longitudinally associated with worsening arterial stiffness, but in type 2 diabetes rather than non-diabetic subjects.
Jang
2019 · Sci Rep
observational supports moderate In 6,462 nondiabetic adults under 65y, higher visit-to-visit HbA1c/fasting/post-load glucose variability was associated with increased macro- and microvascular events.
Sparks
2021 · Int J Environ Res Public Health
observational tested-null low In overweight/obese non-diabetics, 12-wk exercise changed vascular/oxidative markers but CGM glycemic variability did NOT change — decoupling variability from vascular outcomes.
Liao
2026 · Eur J Med Res
meta-analysis mixed low CGM in non-diabetic populations can modify glycemic and behavioral metrics, but the review found no hard-outcome data tying CGM-derived variability to cardiovascular events in healthy people.
Qian
2026 · Diabet Med
mechanism mixed low A perspective argues glycemic variability drives endothelial damage and cardiovascular risk even in pre-diabetes, but this is framed as mechanism and hypothesis, not outcome evidence.
Wu
2025 · Front Endocrinol
meta-analysis mixed moderate HbA1c variability was linked to incident CVD and mortality, but the association is established in type 2 diabetes, not in non-diabetic individuals.
Wilczek
2025 · Sensors (Basel)
observational mixed moderate SR of CGM in non-diabetics: data scarce, effect on cardiovascular outcomes unclear; only potential/surrogate benefit, no hard-endpoint prediction demonstrated.
An
2021 · Eur Rev Med Pharmacol Sci
observational supports moderate Visit-to-visit fasting blood sugar variability was associated with higher cardiovascular disease and mortality risk in a general population that was largely non-diabetic.
Liu
2022 · Diabetes Obes Metab
observational mixed moderate Visit-to-visit glucose variability predicts all-cause mortality — but population is type 2 diabetes, not non-diabetics; not CGM-measured.
Ahmed
2025 · Cureus
observational mixed moderate Systematic review (7 studies) in non-diabetics: higher glycemic variability linked to surrogate markers (e.g. BP variability) but direct evidence on hard cardiovascular endpoints remains limited.
Costantino
2017 · Diabetes
mechanism supports moderate Glycemic variability drives chromatin remodeling, oxidative stress and endothelial dysfunction — but in type 2 diabetics at target HbA1c, not healthy people; mechanism only.
Darouei
2025 · Diabetol Metab Syndr
meta-analysis mixed moderate Glycemic variability (MAGE, SD) predicted adverse cardiovascular events, but the pooled evidence came from patients with pre-existing cardiovascular disease rather than healthy people.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.